Ivabradine is a pure heart rate-lowering agent and was recently approved for the treatment of heart failure ([@ref1]). Ivabradine was approved for use in Europe by the European Medicines Agency for treating patients with heart failure with reduced ejection fraction of ≤35% and those with sinus rhythm with a resting heart rate (HR) ≥75 bpm because it was shown to confer a survival benefit in a subgroup analysis of this patient population ([@ref2]). In the United States, there is a lower HR limit (≥70 bpm) for ivabradine initiation ([@ref3]).

Despite its clinical use, the precise mechanism of its beneficial action in patients with heart failure remains poorly understood. Animal studies have suggested that improved cardiomyocyte calcium handling ([@ref4], [@ref5]), reduced wall stress after myocardial infarction (MI) ([@ref5]), improved coronary reserve due to reduced accumulation of perivascular collagen ([@ref6]), improved diastolic compliance due to reduced fibrosis ([@ref7]), and antiarrhythmic effects due to reduced pathological HCN4 expression in ventricular cardiomyocytes ([@ref8]) play a role in the mechanism of action of ivabradine.

In this issue of The Anatolian Journal of Cardiology, the authors of a paper "Ivabradine promotes angiogenesis and reduces cardiac hypertrophy in mice with myocardial infarction" ([@ref9]) demonstrate that ivabradine administered to mice for 4 weeks after MI improved left ventricular function, reduced hypertrophy, decreased cardiac fibrosis, and increased capillary density. This was accompanied by enhanced Akt-eNOS signaling and inhibited p38 mitogen-activated protein kinase (MAPK) activity. Therefore, they hypothesized that the beneficial effects of ivabradine therapy are associated with the activation of Akt-eNOS signaling.

Akt kinase phosphorylates multiple downstream substrates, including endothelial nitric oxide synthase (eNOS), that are involved in cell survival, proliferation, metabolism, and growth ([@ref10]). Thus, Akt contributes to normal endothelial functions and its activation by vascular endothelial growth factor (VEGF) stimulates endothelial cell proliferation, migration, and survival ([@ref11]) in a nitric oxide (NO)-dependent manner. Indeed, loss of Akt in mouse endothelial cells results in reduced NO release and impaired angiogenesis ([@ref12]).

p38 MAPK is a potent trigger of cardiac hypertrophy ([@ref13]). In the post-MI mouse model, Akt-eNOS activation by ivabradine can also inhibit this pathway; however, indirect effects must also be considered. Better preservation of cardiac function can simply result in fewer stimuli for cardiac hypertrophy.

How does ivabradine stimulate Akt-eNOS signaling? Lei et al. ([@ref14]) offer a potential explanation. They demonstrated that chronic bradycardia induced by alinidine in post-MI rats increased the expression of both VEGF and VEGF receptor, presumably via a stretch-activated mechanism. Therefore, it is possible that increased stretch related to lower HR and increased left ventricular diastolic filling could increase VEGF expression and thus trigger Akt-eNOS signaling. Therefore, NO can indeed be a mediator of the effects of ivabradine.

Obviously, there remain some unanswered questions. Do all heart rate-lowering agents (e.g. beta-blockers) have the same effects on Akt-eNOS signaling? Does this pathway mediate all the beneficial effects of ivabradine? Does it also operate in humans? Future studies are required to address these very important questions.
